Although most of the recent attempts to develop new antiviral agents have been focussed on RNA viruses (in particular, HIV and hepatitis C virus), a few new compounds are now awaiting their entry into the field of DNA viruses, particularly poxviruses, such as variola virus, because of the bioterrorist context, and herpesviruses, such as herpes simplex virus and cytomegalovirus, where the market scene has for many years been dominated by acyclovir, penciclovir and ganciclovir and their respective orally bioavailable prodrugs: valaciclovir, famciclovir and valganciclovir. Here, we review the current 'state of the art' with old compounds ready to rotate off and new compounds eagerly awaiting to appear on the continuously evolving scene of antiviral drug development.
The compound is used for the treatment of mucosal, cutaneous and systemic HSV-1 and HSV-2 infections (including HSV encephalitis and genital herpes), and in VZV infections (including herpes zoster ophthalmicus). It is also used for the prophylaxis of HSV infections (genital herpes) and VZV infections. Extremely safe compound may be used for long-term suppressive therapy. Still regarded as 'gold standard' for HSV therapy. Rather poor oral availability; the oral prodrug is valaciclovir.
GlaxoSmithKline (GSK)
References: [1] [2] [3] Used as its oral prodrug, adefovir dipivoxil, in the treatment of chronic HBV infections.
Acyclovir

Gilead Sciences
References: 1,4,5 Brivudin is used for the treatment of VZV and HSV-1 infections. The compound has been not been licenced in UK, but has mainly been used in Germany and many other countries Berlin Chemie/Menarini References: [9] [10] [11] Brivudin Zostex®, Brivirac®, Zerpex®, Helpin® Fialuridine results in severe liver toxicity.
Adefovir
N O N CH 3 S N S NH 2 O O CH 3 N-[5-aminosulfonyl)-4-methyl-1,3-thiazol-2yl)-N-methyl-[4-(2-pyridinyl) phenyl]acetamide.
Eli Lilly
References: 21, 22 Beecham Research Laboratories Ltd.
References: 18-20 FV-100 is a prodrug of CF-1743. Low-nanomolar activity is claimed suggesting it to be very much more potent than acyclovir against VZV. The BCNAs owe at least part of their antiviral selectivity to a specific activation/phosphorylation by the VZV-encoded thymidine kinase and associated thymidylate kinase (dTMP-K) activity, while being not recognized by the closely related HSV-1-encoded TK/dTMP-K enzyme. In addition, the 5′-monophosphates of BCNAs are neither a substrate nor an inhibitor of the cellular dTMP-K and 5′-deoxynucleotidases. Ganciclovir is used in therapy and prophylaxis of HCMV disease, including retinitis. Toxicity limits its use against HSV. The compound has poor oral bioavailabilty; therefore, an oral prodrug has been formulated: valganciclovir. Idoxuridine is too toxic for systemic administration. Regarded as a 'first generation' nucleoside of great historical importance, but now of limited use (mainly to topically treat HSV keratoconjunctivitis and ophthalmic zoster). The compound has been administered in DMSO for herpes zoster to improve skin penetration with questionable efficacy. Largely replaced by 'second generation' nucleosides.
Bioglan Laboratories, Ferring Pharmaceuticals, GlaxoSmithKline (GSK)
References: 1,35,36 Imiquimod is now owned and marketed in the USA by Graceway Pharmaceuticals and in Europe by Meda, AB (Sweden). The compound induces cytokines including interferons via a toll-like receptor 7 activation. Topical application is licensed for the treatment of genital and perianal warts caused by HPV and also for the skin cancer conditions superficial basal cell carcinoma and actinic keratosis.
Idoxuridine
Herpid®, Stoxil®
3M Pharmaceuticals
References: [37] [38] [39] Imiquimod Aldara® GlaxoSmithKline (GSK), ViroPharma Inc. Marketed by Novartis. Similar to acyclovir with similar resistance profile, but appears to have longer intracellular half-life than acyclovir. A 1% cream (Vectavir ® ) is licensed for topical therapy for cutaneous HSV-1 infections (herpes labialis). The oral bioavailabilty is very low and the prodrug form, famciclovir, is among the first of the successful antiviral prodrugs. As famciclovir, it is used for VZV infections. The most successful of several compounds formulated to overcome the poor oral bioavailability of acyclovir. After oral administration is cleaved in gut and liver to yield acyclovir and the natural amino acid l-valine. Used for the treatment of mucosal, cutaneous and systemic HSV-1 and HSV-2 infections and VZV. It is also used for the long-term suppression of recurrent HSV infections.
GlaxoSmithKline (GSK)
References: 59-61 Valganciclovir is a prodrug of ganciclovir. The compound is rapidly converted to ganciclovir -by intestinal and hepatic esterases -increasing its oral bioavailability to approximately 60%. Valomaciclovir stearate is a prodrug of H2G; it is rapidly converted to H2G.
Valaciclovir
Valtrex®, Zelitrex®
Medivir, Epiphany Bioscience
References: [64] [65] [66] Valomaciclovir stearate 
